Dow Jones
33.002,38 -430,97 (-1,29%) Nasdaq
13.059,47 -248,31 (-1,87%) Nikkei 225
30.745,10 -492,84 (-1,58%) EUR/USD
1,0474 +0,0005 (+0,05%) Bitcoin EUR
26.082,80 -126,78 (-0,48%) CMC Crypto 200
582,46 -7,51 (-1,27%)
Terumo Corp (TUO.BE)
| Chiusura precedente | 24,60 |
| Aperto | 24,20 |
| Denaro | 24,00 x 0 |
| Lettera | 24,60 x 0 |
| Min-Max giorno | 24,20 - 24,20 |
| Intervallo di 52 settimane | 24,20 - 30,60 |
| Volume | |
| Media Volume | 1 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireOrchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
U.S. Food and Drug Administration (“FDA”) granted Investigational Device Exemption (“IDE”) approval with conditions for Virtue SAB® coronary in-stent restenosis (“ISR”) U.S. pivotal study (in collaboration with Terumo Corporation (“Terumo”)); study expected to start before the end of 2023BackBeat CNT™ global pivotal study in hypertensive pacemaker patients (in collaboration with Medtronic) on track for initiation in the second half of 2023 NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orchest
- GlobeNewswire
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of extended release sirolimus under clinical investigation worldwideVirtue ISR-US pivotal study focused on coronary in-stent restenosis (“ISR”), a difficult-to-treat and serious complication of coronary stenting, currently expected to start before the end of 2023Strategic partnership with Terumo Corporation (“Terumo”) targets coronary ISR and multiple additional vascular indicat
